Andrew Huberman· PhD
There's also very little incentive for drug companies to invest in those because they've passed through their um, patent window. So, there's not a lot of money to be made.
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
There's also very little incentive for drug companies to invest in those because they've passed through their um, patent window. So, there's not a lot of money to be made.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.